|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2640 EUR | +0.76% |
|
-6.38% | +55.29% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Therapeutic Devices | ||||||||||
Cardiology | - | - | 102K | 186K | 21K | |||||
Interest Expense | 107K | -19K | - | - | - | |||||
EBT | -143K | -669K | -716K | -209K | -739K | |||||
Gross Profit | - | - | 33K | 173K | 13K | |||||
Operating Income | -250K | -650K | -716K | -209K | -739K | |||||
Net Income | - | -669K | -716K | -209K | -739K | |||||
Biological Products | ||||||||||
Immuno-Oncology | - | - | - | - | - | |||||
Interest Expense | -165K | -132K | -52K | - | -41K | |||||
Income Tax Expense | - | 65K | -65K | - | - | |||||
EBT | -16.44M | -29.73M | -2.6M | -2.77M | 4.76M | |||||
Gross Profit | - | - | - | - | - | |||||
Operating Income | -16.28M | -29.6M | -2.54M | -2.71M | 4.8M | |||||
Net Income | - | -29.8M | -2.53M | -2.77M | 4.76M | |||||
Net Income | - | -10.47M | -5.2M | -2.85M | -3.18M | |||||
Operating Income | -9.86M | -10.61M | -5.2M | -2.94M | -3.17M | |||||
Income Tax Expense | - | - | 2K | - | - | |||||
EBT | -9.92M | -10.47M | -5.2M | -2.85M | -3.18M | |||||
Interest Expense | -53K | 138K | -2K | - | -11K |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Total Assets | - | - | - | - | - | |||||
Total Assets | 45.65M | 4.89M | 5.16M | 3.41M | 801K |
- Stock Market
- Stocks
- CYAD Stock
- Financials Celyad Oncology SA
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition